藥明康德(02359.HK)稱業務營運仍以正常節奏進行 績後股價仍挫逾6%
藥明康德(02359.HK)在業績電話會上稱,在美國《生物安全法》草案發布後,公司與客戶之間保持著密切溝通,並向客戶提供相關進展。目前來看,認為公司業務及客戶關係仍然牢固,從今年首兩個月新簽訂單來看,業務運作仍按正常節奏進行。
藥明康德昨日(19日)公布,去年純利106.9億人民幣,按年增長21.3%,末期息每10股派9.8336元人民幣。瑞銀及野村認為,藥明康德今年指引低於市場預期,分別將其目標價下調至44及54.56元。藥明康德股價現跌6.67%,報39.9元,成交1,188.28萬股,涉資4.7億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.